INDOCO REMEDIES Financial Statement Analysis
|
||
|
The Revenues of INDOCO REMEDIES have increased by 8.30% YoY .
The Earnings Per Share (EPS) of INDOCO REMEDIES has decreased by -30.83 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
INDOCO REMEDIES Last 5 Annual Financial Results
[BOM: 532612|NSE : INDOCO]
| Consolidated | Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 |
|---|---|---|---|---|---|
| Revenues | ₹1,669 Cr | ₹1,541 Cr | ₹1,242 Cr | ₹1,107 Cr | ₹968 Cr |
| Expenses | ₹1,383 Cr | ₹1,215 Cr | ₹1,023 Cr | ₹986 Cr | ₹892 Cr |
| Operating Profit (Excl OI) | ₹286 Cr | ₹326 Cr | ₹218 Cr | ₹121 Cr | ₹77 Cr |
| Other Income | ₹2.38 Cr | ₹3.42 Cr | ₹9.06 Cr | ₹4.80 Cr | ₹6.70 Cr |
| Interest | ₹25 Cr | ₹14 Cr | ₹22 Cr | ₹26 Cr | ₹21 Cr |
| Depreciation | ₹71 Cr | ₹79 Cr | ₹73 Cr | ₹71 Cr | ₹72 Cr |
| Profit Before Tax | ₹193 Cr | ₹237 Cr | ₹132 Cr | ₹29 Cr | ₹-9.31 Cr |
| Profit After Tax | ₹142 Cr | ₹155 Cr | ₹93 Cr | ₹24 Cr | ₹-2.90 Cr |
| Consolidated Net Profit | ₹142 Cr | ₹155 Cr | ₹93 Cr | ₹24 Cr | ₹-2.90 Cr |
| Earnings Per Share (Rs) | ₹10.68 | ₹15.44 | ₹16.80 | ₹10.10 | ₹2.62 |
| PAT Margin (%) | 5.34 | 8.53 | 10.05 | 7.49 | 2.18 |
| ROE(%) | 9.09 | 14.72 | 18.50 | 12.85 | 3.60 |
| ROCE(%) | 11.25 | 17.48 | 23.03 | 15.67 | 5.78 |
| Total Debt/Equity(x) | 0.59 | 0.31 | 0.27 | 0.34 | 0.39 |
Key Financials |
||
| Market Cap | : | ₹ 3,115.4 Cr |
| Revenue (TTM) | : | ₹ 1,773.2 Cr |
| Net Profit(TTM) | : | ₹ 29.4 Cr |
| EPS (TTM) | : | ₹ 3.2 |
| P/E (TTM) | : | 106.0 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| INDOCO REMEDIES | 1.7% | 5.2% | -15.8% |
| SUN PHARMACEUTICAL INDUSTRIES | 0.9% | 4.4% | 50% |
| CIPLA | 2.1% | 0.2% | 22.8% |
| DR REDDYS LABORATORIES | -1.1% | 12.1% | 18.1% |
| ZYDUS LIFESCIENCES | 1.8% | 0.9% | 41.3% |
| DIVIS LABORATORIES | 4.6% | -1.1% | 55.6% |
| MANKIND PHARMA | 0.9% | 13.3% | 45.6% |
| TORRENT PHARMACEUTICALS | 1.2% | 2.5% | 48.2% |
| LUPIN | 7.6% | 15.1% | 78.8% |
INDOCO REMEDIES Revenues
[BOM: 532612|NSE : INDOCO]
| Y-o-Y | 8.30 % |
| 5 Yr CAGR | 14.57 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2024 | ₹1,669 Cr | 8.30 | |
| Mar2023 | ₹1,541 Cr | 24.10 | |
| Mar2022 | ₹1,242 Cr | 12.19 | |
| Mar2021 | ₹1,107 Cr | 14.26 | |
| Mar2020 | ₹968 Cr | - | |
INDOCO REMEDIES Operating Profit
[BOM: 532612|NSE : INDOCO]
| Y-o-Y | -12.32 % |
| 5 Yr CAGR | 38.99 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2024 | ₹286 Cr | -12.32 | |
| Mar2023 | ₹326 Cr | 49.43 | |
| Mar2022 | ₹218 Cr | 80.67 | |
| Mar2021 | ₹121 Cr | 57.66 | |
| Mar2020 | ₹77 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -19.04 % |
| 5 Yr CAGR | 21.33 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2024 | 17.14% | -19.04 | |
| Mar2023 | 21.17% | 20.35 | |
| Mar2022 | 17.59% | 61.08 | |
| Mar2021 | 10.92% | 38.05 | |
| Mar2020 | 7.91% | - | |
INDOCO REMEDIES Profit After Tax
[BOM: 532612|NSE : INDOCO]
| Y-o-Y | -8.11 % |
| 5 Yr CAGR | Positive |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2024 | ₹142 Cr | -8.11 | |
| Mar2023 | ₹155 Cr | 66.37 | |
| Mar2022 | ₹93 Cr | 285.81 | |
| Mar2021 | ₹24 Cr | Positive | |
| Mar2020 | ₹-2.90 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | -37.40 % |
| 5 Yr CAGR | 25.10 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2024 | 5.34 % | -37.40 | |
| Mar2023 | 8.53 % | -15.12 | |
| Mar2022 | 10.05 % | 34.18 | |
| Mar2021 | 7.49 % | 243.58 | |
| Mar2020 | 2.18 % | - | |
INDOCO REMEDIES Earnings Per Share (EPS)
[BOM: 532612|NSE : INDOCO]
| Y-o-Y | -30.83 % |
| 5 Yr CAGR | 42.09 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2024 | ₹11 | -30.83 | |
| Mar2023 | ₹15 | -8.10 | |
| Mar2022 | ₹17 | 66.34 | |
| Mar2021 | ₹10 | 285.50 | |
| Mar2020 | ₹2.62 | - | |
INDOCO REMEDIES Return on Capital Employed (ROCE)
[BOM: 532612|NSE : INDOCO]
| Y-o-Y | -35.64 % |
| 5 Yr CAGR | 18.12 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2024 | 11.25% | -35.64 | |
| Mar2023 | 17.48% | -24.10 | |
| Mar2022 | 23.03% | 46.97 | |
| Mar2021 | 15.67% | 171.11 | |
| Mar2020 | 5.78% | - | |
INDOCO REMEDIES Share Price vs Sensex
| Current Share Price | : | ₹337.9 |
| Current MarketCap | : | ₹ 3,115.4 Cr |
| Updated EOD on | : | Jan 02,2025 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| INDOCO REMEDIES | 1.7% |
5.2% |
-15.8% |
| SENSEX | 1.9% |
-0.4% |
10.4% |
INDOCO REMEDIES related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| S&P BSE HEALTHCARE | 3.1% | 3.3% | 44.8% |
| S&P BSE SMALL CAP | 2.3% | 0.8% | 32.4% |
| S&P BSE MIDSMALLCAP | 1.1% | 1.2% | 30.3% |
| S&P BSE ALLCAP | -0.3% | -3.5% | 35.8% |
No NSE index found
You may also like the below Video Courses
FAQ about INDOCO REMEDIES Financials
How the annual revenues of INDOCO REMEDIES have changed ?
The Revenues of INDOCO REMEDIES have increased by 8.30% YoY .
How the Earnings per Share (EPS) of INDOCO REMEDIES have changed?
The Earnings Per Share (EPS) of INDOCO REMEDIES has decreased by -30.83 % YoY .
Check out Intrinsic Value of Peers of INDOCO REMEDIES
Compare Stock Analytics of Peers of INDOCO REMEDIES
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
